A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBI-0451 in Healthy Subjects.
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Pomotrelvir (Primary) ; Midazolam; Ritonavir
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Pardes Biosciences
- 01 Jun 2022 Status changed from recruiting to completed.
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 14 Feb 2022 According to Pardes Biosciences media release, Additional dose cohorts and PK evaluation in this ongoing Phase 1 study continues and will inform dose selection for the upcoming PBI-0451 Phase 2/3 study anticipated to start mid 2022 (pending regulatory interactions)